Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/14152
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.otherProducción Científica UCH 2022-
dc.contributor.otherUCH. Departamento de Ciencias Biomédicas-
dc.creatorIbáñez Company, Mariam-
dc.creatorSuch Taboada, Esperanza-
dc.creatorLiquori, Alessandro-
dc.creatorAndreu Lapiedra, Rafael-
dc.creatorVicente, Ana-
dc.creatorAvestisyan, Gayane-
dc.date2022-
dc.date.accessioned2023-03-14T05:00:30Z-
dc.date.available2023-03-14T05:00:30Z-
dc.date.issued2022-04-11-
dc.identifier.citationIbáñez, M., Such, E., Liquori, A., Avestisyan, G., Andreu, R., Vicente, A. et al. (2022). Panel sequencing for clinically oriented variant screening and copy number detection in chronic lymphocytic leukemia patients. Diagnostics, vol. 12, i. 4 (11 apr.), art. 953. DOI: https://doi.org/10.3390/diagnostics12040953-
dc.identifier.issn2075-4418 (Electrónico)-
dc.identifier.urihttp://hdl.handle.net/10637/14152-
dc.descriptionEste artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.mdpi.com/2075-4418/12/4/953-
dc.descriptionEn esta investigación también participan: María José Macián, Mari Carmen Meléndez, Mireya Morote-Faubel, Pedro Asensi, María Pilar Lloret, Isidro Jarque, Isabel Picón, Alejandro Pacios, Eva Donato, Carmen Mas-Ochoa, Carmen Alonso, Carolina Cañigral, Amparo Sempere, Samuel Romero, Marta Santiago, Guillermo F. Sanz, Javier de la Rubia, Leonor Senent e Irene Luna.-
dc.descriptionEste artículo de investigación pertenece a la sección "Pathology and Molecular Diagnostics".-
dc.description.abstractAccording to current guidelines, in chronic lymphocytic leukemia (CLL), only the TP53 molecular status must be evaluated prior to every treatment’s initiation. However, additional heterogeneous genetic events are known to confer a proliferative advantage to the tumor clone and are associated with progression and treatment failure in CLL patients. Here, we describe the implementation of a comprehensive targeted sequencing solution that is suitable for routine clinical practice and allows for the detection of the most common somatic single-nucleotide and copy number variants in genes relevant to CLL.We demonstrate that this cost-effective strategy achieves variant detection with high accuracy, specificity, and sensitivity. Furthermore, we identify somatic variants and copy number variations in genes with prognostic and/or predictive value, according to the most recent literature, and the tool provides evidence about subclonal events. This next-generation sequencing (NGS) capture-based target assay is an improvement on current approaches in defining molecular prognostic and/or predictive variables in CLL patients.-
dc.formatapplication/pdf-
dc.language.isoen-
dc.publisherMDPI-
dc.relation.ispartofDiagnostics, vol. 12, i. 4 (11 apr. 2022)-
dc.rightshttp://creativecommons.org/licenses/by/4.0/deed.es-
dc.subjectMolecular genetics.-
dc.subjectGenética molecular.-
dc.subjectChronic lymphocytic leukemia - Genetic aspects.-
dc.subjectLeucemia linfocítica crónica - Aspectos genéticos.-
dc.titlePanel sequencing for clinically oriented variant screening and copy number detection in chronic lymphocytic leukemia patients-
dc.typeArtículo-
dc.centroUniversidad Cardenal Herrera-CEU-
Aparece en las colecciones: Dpto. Ciencias Biomédicas




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.